News ListTuesday August 14, 2007 Ipsogen grants Warnex exclusive rights, for the Canadian territory, to market a service for the diagnosis and the classification of a group of leukemiasIpsogen SAS. today announced the signature of an exclusive agreement with Warnex Inc. (TSX: WNX), a life sciences company devoted to protecting public health by providing laboratory services to the pharmaceutical and healthcare... Category: Corporate
 Tuesday August 07, 2007 Ipsogen expands and opens New Haven office to market its leukaemia molecular diagnostic products in North AmericaIpsogen, Inc., founded in March 2005 as a subsidiary of Ipsogen SAS, a leading provider of molecular diagnostics in oncology headquartered in Marseille, France, today announced the opening of its new facilities in New Haven,... Category: Corporate
Thursday May 24, 2007 Ipsogen is part of COBRED, a breast & colon cancer biomarker European project.Marseille, France, May 24, 2007 – IPSOGEN today announced that COBRED project coordinated by BioSystems International (Paris) has been awarded a 2.9 M€ grant as part of the 6th Framework Programme.
COBRED project aims at... Category: Breast Cancer
 Thursday May 24, 2007 Ipsogen part of a 2.9 M€ granted European project dedicated to breast and colon cancer biomarker research - ‘COBRED project’IPSOGEN today announced that COBRED project coordinated by BioSystems International (Paris) has been awarded a 2.9 M€ grant as part of the 6th Framework Programme.COBRED project aims at discovering breast cancer (BC) and colon... Category: Breast Cancer
Wednesday December 13, 2006 Ipsogen and anti cancer centres to initiate a prospective clinical trial for use of a genomic signature for managing chemotherapeutic options in breast cancerMarseille, France, December 13, 2006 Read more – Ipsogen SAS, a French biotechnology company and a group of comprehensive cancer centres led by Institut Paoli-Calmettes (IPC) today announced that the clinical trial SA02 is... Category: Breast Cancer
Friday March 31, 2006 IPSOGEN licenses JAK2 mutation test to improve the diagnosis of blood-based disordersMarseille, France, March 30, 2006 Read more – IPSOGEN SAS, a molecular diagnostic company developing tests to improve disease management of cancer patients, announced today the signature of a license agreement with Institut... Category: Leukemia
 Friday February 24, 2006 Ipsogen presents breast cancer biomarker results at the upcoming EBCC 5, the 5th European Breast Cancer ConferenceMarseille, France, February 24, 2005 – Ipsogen SAS, the French cancer diagnostics company, announced today that its latest breast cancer program results had been selected for presentation at the EBCC 5 congress, the 5th European... Category: Breast Cancer
Thursday October 13, 2005 Ipsogen presents breast cancer biomarker results at the European Cancer Conference ECCO 13Marseille, France, October 13, 2005 – The abstract titled "Utilisation of microarray technology to refine molecular classes and improve clinical management of breast cancer," has been selected by the ECCO 13... Category: Breast Cancer
Friday June 24, 2005 Ipsogen receives 2005 "Price for Innovation"Marseille, France, June, 23th 2005 For 4 years, Siemens, a world leader of the patent registration of invention, with 5000 patents registered last year, awards trophies to the most innovative companies in France. The main... Category: Corporate
Thursday May 19, 2005 Genaissance Pharmaceuticals and Ipsogen announce cancer biomarker research agreementsNew Haven, CT, and Marseille, France, September 12, 2005 – Read more Privately-held Ipsogen SAS and Genaissance Pharmaceuticals, Inc. (NASDAQ: GNSC) announced today that they have signed collaboration agreements with two... Category: Corporate
|
|
